Google
LXRX — LEXICON PHARMACEUTICALS INC (Healthcare >> Biotechnology)
LXRX FAQ
What is LXRX's P/E ratio?
LEXICON PHARMACEUTICALS INC (LXRX) currently trades at a P/E ratio of 259.52.
What is LXRX's ROE?
LEXICON PHARMACEUTICALS INC reports a Return on Equity (ROE) of -12.86%.
What is LXRX's dividend yield?
LEXICON PHARMACEUTICALS INC offers a dividend yield of 0.00%.
What is LXRX's Deepscope Quality Score?
Deepscope rates LXRX's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy LXRX?
Deepscope's AI Timing Score for LXRX is 70 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does LXRX belong to?
LEXICON PHARMACEUTICALS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 1.91
Price
0.01
(0.53%)
Day Change
|
|
|---|
LXRX, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 95 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.91 |
| PBV / Sector |
4.16 / 4.63
|
| Earning Per Share | -0.06 |
| PE / Sector |
259.52 / 17.43
|
| PEG or PE/Growth / Sector |
-11.21 / 0.53
|
| Average 1M Daily Value |
6.90 M
|
| Average 1W Daily Value |
4.25 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
47% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:09:02 |
| Symbol | LXRX |
| Name | LEXICON PHARMACEUTICALS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 444.20 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 843.97 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2445 Technology Forest Boulevard, The Woodlands, TX, United States, 77381
Phone: 281 863 3000
Website: https://www.lexpharma.com
Employees: 81
Sector: Healthcare >> Biotechnology
Description: Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
